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Abstract 
Several lines of evidence suggest that oxidative stress plays a role in the mechanisms of action 
of methamphetamine (MAP) in the human brain. Given the role of glutathione S-transferases 
(GSTs) in the protection against oxidative stress, genes encoding the GSTs have been 
considered as candidates for association studies of MAP abuse. This study was undertaken to 
investigate the role of the functional polymorphism of GSTP1 gene exon 5 (Ile105Val) in the 
pathogenesis of MAP abuse. Genotyping for GSTP1 gene polymorphism exon 5 (Ile105Val) in 
189 MAP abusers and 199 normal controls was performed by polymerase chain reaction 
(PCR)-restriction fragment length polymorphism. Association between GSTP1 gene 
polymorphism and clinical features (prognosis of psychosis (transient-type and 
prolonged-type), spontaneous relapse (positive and negative), and poly-substance abuse) of 
MAP abusers was evaluated. Significant differences in the frequency of both alleles (p = 0.026, 
odds ratio: 1.70, 95% confidence intervals (CI) 1.06-2.72) and genotypes (p=0.029) between 
MAP abusers and controls were detected. In particular, a significant difference in both 
genotype frequency (p=0.013) and allele frequency (p=0.014, odds ratio: 1.84, 95% CI 
1.13-2.97) between MAP abusers with psychosis (transient-type and prolonged-type) and 
controls was detected. Our findings suggest that the polymorphism (Ile105Val) on exon 5 of 
the GSTP1 gene may contribute to a vulnerability to psychosis associated with MAP abuse in 
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Japanese population. 
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Introduction 
Abuse of methamphetamine (MAP) is a growing problem worldwide. Some lines of 
evidence suggest that both environmental and genetic factors might contribute to drug abuse 
vulnerability [Cami and Farre, 2003; Rawson et al., 2002; Merikangas et al., 1998; Kendler et 
al., 2000; Uhl et al., 2002]. It is well known that MAP induces a strong psychological 
dependence, and that repeated further consumption of MAP results in psychotic states, the 
symptoms of which resemble those of the paranoid type of schizophrenia [Sato et al., 1983; 
Sato et al., 1992].  
Positron emission tomography (PET) imaging studies of the brains of MAP abusers have 
demonstrated that the density of dopamine (DA) transporters is significantly decreased in the 
caudate/putamen of MAP abusers [Volkow et al., 2001; Sekine et al., 2001]. Such findings 
suggest that the long-term use of MAP leads to the damage of dopaminergic neurons in the 
human brain. It has been shown that MAP-induced neurotoxicity in the brain requires the 
involvement of striatum DA and also involves mechanisms associated with oxidative stress, 
further suggesting that oxidative stress in dopaminergic pathways might be implicated in 
MAP-induced neurotoxicity [Cadet et al., 2003]. There are a number of papers demonstrating 
the neuroprotective effects of glutathione or its related compounds on MAP- or DA-induced 
neurotoxicity [Choi et al., 2002; Fukami et al., 2004; Hashimoto et al., 2004; Shimizu et al., 
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2002]. In addition, it is also well known that dopaminergic pathways in the mesocorticolimbic 
systems can play an important role in drug reward [Kalivas, 2002]. Therefore, polymorphisms 
in genes that regulate dopaminergic pathways may contribute to interindividual differences as 
regards a vulnerability to drug abuse [Koob and LeMoal, 1997].  
The glutathione S-transferases (GSTs: EC 2.5.1.18) belong to a family of multifunctional 
enzymes that catalyze the conjugation of reduced glutathione with electrophilic groups of a 
wide variety of compounds including carcinogens, environmental contamination, and products 
of the oxidative process [Mannervik 1985; Hayes and Strange, 2000; Smythies and Galzigma, 
1998]. Because of their important role in the cellular defense against oxidative stress, GSTs are 
of interest in the context of association studies of MAP abuse. The genes encoding three 
classes of GSTs, i.e., GSTM (mu, chromosome 1p13.3), GSTP (pi, chromosome 11q13), and 
GSTT1 (theta, chromosome 22q11.2), are known to be polymorphic [Stucker et al., 2002; De 
Roos et al., 2003; Kelada et al., 2003; Wang et al., 2003; Watson et al., 1998]. Recently, we 
reported an association between GSTM1 gene deletion and female MAP abusers, suggesting 
that GSTM1 gene deletion may contribute to a vulnerability to MAP abuse in Japanese 
subjects [Koizumi et al., 2004]. Furthermore, it has been reported that genetic polymorphisms 
of GSTP1 exon 5 (rs947894, Ile105Val (A>G)) and exon 6 (rs1799811, Ala114Val (C>T)) 
have functional relevance to the GST gene product resulting in reduced GST enzyme activity 
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(~30%) [Watson et al., 1998; Board et al., 1989; Zimniak et al., 1994; Ali-Osman et al., 1997]. 
Taken together, such findings appear to suggest that individuals with these variant GSTP1 
genotypes which result in reduced GSTP1 enzymatic activity may be at greater risk of MAP 
abuse. In order to verify the potential role of the GSTP1 gene in the pathogenesis of MAP 
abuse, we analyzed a polymorphism of the GSTP1 gene in subjects with a diagnosed 
MAP-related disorder. 
 
Methods 
This study was performed after obtaining the approval of the ethics committees of each 
affiliated institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA). All subjects 
provided written informed consent for the use of their DNA samples for this study. The 
subjects were 189 patients (149 males and 40 females, age: 36.9 ±11.9 years (mean ± SD), age 
range: 18 -69 years) with MAP dependence and a psychotic disorder meeting the ICD-10-DCR 
criteria (F15.2 and F15.5) who were outpatients or inpatients of psychiatric hospitals of the 
JGIDA (Table 1). The control subjects were 199 age-, gender-, and geographical 
origin-matched normal controls (157 males and 42 females, age: 37.2 ± 10.5 years (mean ± 
SD), age range: 19-73 years), the majority of whom were with no past history and no family 
history of drug dependence or psychotic disorders. Diagnoses were made by two trained 
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psychiatrists by interview and available information including hospital records. Patients were 
excluded if they had a clinical diagnosis of schizophrenia, another psychotic disorder, or an 
organic mental syndrome as reported previously [Ujike et al., 2003]. All subjects were 
Japanese, born and living in restricted areas of Japan including northern Kyushu, Setouchi, 
Tyukyou, Toukai, and Kantou.  
The patients were divided into subgroups by some characteristic clinical features (Table 
1). The patients were divided by poly-substance abuse status, 55 patients abuse MAP only in 
their lifetime, and 116 patients abuse some other drugs besides MAP in present or past. 
Organic solvent was most frequently abused besides MAP, followed by marijuana. Cocaine 
and heroine were rarely abused in the present study. Prognosis of MAP psychosis was various 
among patients, and some patients showed continuous psychotic symptoms even after MAP 
discontinuance as previously reported [Sato et al., 1983; Sato et al., 1992]. Therefore, patients 
were divided into two categories of prognosis, transient-type and prolonged-type, based on 
duration of psychotic state after MAP discontinuance. Thus, patients with transient-type whose 
psychotic symptoms improves within one month after discontinuance of MAP consumption 
and beginning of treatment with antipsychotic drugs, and those with prolonged-type whose 
psychosis continues for more than one month even after discontinuance of MAP consumption 
and beginning of treatment. In this study, patients with transient- and prolonged-types of MAP 
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psychosis were 94 and 65, respectively (Table 1). It has been well documented that once MAP 
psychosis has developed, patients in remission state becomes reliable to spontaneous relapse 
without re-consumption of MAP [Sato et al., 1983; Sato et al., 1992]. It is postulated that 
sensitization phenomenon induced by repeated consumption of MAP should be developed in 
the brain of MAP psychosis patients which result in neural basis for enhanced susceptibility to 
relapse. Therefore, the patients were divided into two groups according to presence or absence 
of spontaneous relapse. The patients with and without spontaneous relapse were 62 and 111, 
respectively (Table 1). 
Two polymorphisms on exon 5 and exon 6 of the GSTP1 gene have previously been 
reported. We analyzed exon 5 (rs947894, Ile105Val) of the GSTP1 gene in this study, since no 
minor allele frequency of the polymorphism of exon 6 (rs1799811, Ala114Val) was detected 
among Japanese normal subjects [Ishii et al., 1999]. Genotyping for this gene was performed 
by PCR-RFLP analysis. The polymorphic site in exon 5 (Ile105Val) was amplified as reported 
previously [Wang et al., 2003]. The primers of exon 5 of the GSTP1 gene were GSTP1-5F 
(5’-GTAGTTTGCCCAAGGTCAAG-3’) and GSTP1-5R 
(5’-AGCCACCTGAGGGGTAAG-3’). After performing PCR, a 433 bp DNA fragment was 
amplified for GSTP1 exon 5, followed by 2-hr digestion with BsmA I (New England Biolabs, 
Inc., Beverly, MA, U.S.A.). The fragments were separated on 2% agarose gel stained with 
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ethidium bromide. The wild-type (A/A), heterozygous genotype (A/G), and mutant genotype 
(G/G) yielded 2 bands (328 and 105 bp), 4 bands (328, 222, 106, and 105 bp), and 3 bands 
(222, 106, and 105 bp), respectively.  
 The differences between groups were evaluated by Fisher’s exact test. The odds ratio 
and 95 % confidence intervals (CI) between two variables were calculated as an estimate of 
risk. Differences were considered significant at p<0.05.   
 
Results 
The frequencies of allele and genotypes in MAP abusers and controls are shown in Tables 
2. The genotype distribution in both MAP abusers and controls was in the Hardy-Weinberg 
equilibrium. The differences in both genotype frequency (p=0.029) and allele frequency 
(p=0.026) between MAP abusers and controls were found to be significant (Table 2). The 
frequency of carrying the G allele in MAP abusers was significantly higher (p=0.026, odds 
ratio: 1.70, 95% CI 1.06-2.72) than that of controls.  
Next, we examined the association between the clinical features of MAP abusers (i.e., 
prognosis of psychosis, spontaneous relapse, and poly-substance abuse) and normal controls. A 
significant difference in both genotype frequency (p=0.013) and allele frequency (p=0.014, 
odds ratio: 1.84, 95% CI 1.13-2.97) between MAP abusers with psychosis (transient-type and 
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prolonged-type) and controls was detected (Table 2). There was a significant difference in 
genotype frequency (p=0.045) between MAP abusers with transient-type psychosis and 
controls, and was a trend toward difference in allele frequency (p=0.052, odds ratio: 1.75, 95% 
CI 1.01-3.06) between MAP abusers with transient-type psychosis and controls. There was 
also a significant difference in both genotype frequency (p=0.028) and allele frequency 
(p=0.039, odds ratio: 1.96, 95% CI 1.07-3.59) between MAP abusers with prolonged-type 
psychosis and controls. Furthermore, a significant difference in terms of both genotype 
frequency (p=0.009) and allele frequency (p=0.009, odds ratio: 2.00, 95% CI 1.19-3.35) 
between MAP abusers with negative spontaneous relapse and controls was detected (Table 2). 
Moreover, there was a trend toward difference in both genotype frequency (p=0.052) and allele 
frequency (p=0.053, odds ratio: 1.70, 95% CI 1.00-2.88) between MAP abusers with 
poly-substance abuse and controls (Table 2).  
 
Discussion 
Our findings suggest that a functional polymorphism (Ile105Val) on exon 5 of the 
GSTP1 gene may contribute to MAP abuse vulnerability in Japanese subjects. Since a 
polymorphism (Ile105Val) on exon 5 has been shown to be of functional significance in terms 
of enzyme activity [Watson et al., 1998; Zimniak et al., 1994], individuals with the G allele 
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(valine) would be expected to have decreased GST detoxification. Based on the role of GSTs in 
the antioxidant system preventing MAP-induced neurotoxicity, variant GSTP1 genes might 
lead to an excess of metabolic products (e.g., DA-quinone) of the oxidative process induced by 
the administration of MAP, and may furthermore lead to MAP-induced neurotoxicity in the 
brain, including damage of the dopaminergic neurons, as compared to the products associated 
with the A allele (isoleucine) of GSTP1 gene. We also found that the frequency of the G allele 
in MAP abusers with psychosis (transient-type and prolonged-type) was significantly higher 
than that of controls, suggesting that this GSTP1 gene polymorphism may be associated with 
MAP-induced psychosis in Japanese subjects. Thus, it appears to be the case that the GSTP1 
polymorphism (Ile105Val) on exon 5 may contribute to a susceptibility to MAP-induced 
psychosis among Japanese subjects. In contrast, we found an association between GSTP1 
polymorphism (Ile105Val) and negative spontaneous relapse, whereas no association between 
this polymorphism and positive spontaneous relapse was detected. Taken together, it seems 
that GSTP1 polymorphism (Ile105Val) may be implicated in MAP-induced psychosis, but not 
spontaneous relapse, although further studies using a large sample are necessary. 
It has been suggested that DA-quinones synthesized by auto-oxidation of DA might play a 
role in MAP-induced neurotoxicity in the brain, and that glutathione and GST might play a 
role in the detoxification against DA-quinone induced neurotoxicity [Smythies and Galzigna, 
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1998; LaVoie and Hastings, 1999, Whitehead et al., 2001; Shimizu et al., 2002; Asanuma et al., 
2003]. Thus, DA auto-oxidation results in the formation of DA-quinones, which readily 
participate in nucleophilic addition reactions with sulfhydryl groups on free cysteine, 
glutathione, or cysteine found in proteins including DA transporters [Smythies and Galzigna, 
1998; Whitehead et al., 2001]. Based on the known role of GSTs in the process of antioxidant 
defense, we considered the possibility that MAP abusers with the G allele of GSTP1 
polymorphism were more susceptible to MAP-induced psychosis or to a spontaneous relapse 
of MAP abuse. In this study, we found significant differences in the distribution of genotype 
and allele frequencies between MAP abusers with psychosis and controls. Furthermore, we 
found a significant difference between MAP abusers with negative spontaneous relapse and 
controls. Taken together, it is likely that the polymorphism (Ile105Val) on exon 5 of the GSTP1 
gene could be a risk factor for the development of MAP-induced psychosis in Japanese 
subjects.  
It is reported that the frequency (18 %) of the G allele in Asians such as Taiwanese is 
lower than that in African-American (42 %) and European-American (33 %)[Watson et al., 
1998]. The frequency of (8 %; our study) of the G allele in Japanese control subjects is 
significantly (x2=13.3, p=0.0003) lower than that (18 %) of Taiwanese, suggesting the ethnic 
difference between Asians and European- and African-Americans for the polymorphism 
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(Ile105Val) on exon 5 of GSTP1. Therefore, it may be of interest to examine the association 
between the GSTP1 gene polymorphism and methamphetamine abusers in European- and 
African-Americans. If replication studies are confirmed, the polymorphism (exon 5 Ile105Val) 
of GSTP1 would be only the known specific mechanism by which genetic variation leads to a 
risk for the development of MAP-induced psychosis. Interestingly, our recent PET study 
demonstrated that the antioxidant N-acetyl-L-cysteine (a precursor for glutathione synthesis) 
could attenuate significantly the reduction of DA transporter in monkey striatum after repeated 
administration of MAP [Hashimoto et al., 2004]. In addition, we reported that 
N-acetyl-L-cysteine attenuated hyperlocomotion, development of sensitization, and 
neurotoxicity after administration of MAP [Fukami et al., 2004], suggesting that 
N-acetyl-L-cysteine would be a suitable drug for treatment of MAP abuse. As described in 
Introduction, it is likely that endogenous antioxidant glutathione plays a role in the behavioral 
changes and neurotoxicity associated with MAP abuse. Taken together, our findings may shed 
light on some of the neurobiological mechanisms and pathways that lead to the development of 
MAP abuse, and could thereby facilitate the development of novel treatments and prevention 
strategies for MAP abuse. 
In conclusion, our findings indicate that a polymorphism (exon 5 Ile105Val) of the 
GSTP1 gene may contribute to a vulnerability to MAP abuse among Japanese subjects. 
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Furthermore, it is likely that this polymorphism (exon 5 Ile105Val) of the GSTP1 gene could 
be a risk factor for the development of MAP-induced psychosis in Japanese subjects. 
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Table 1. Characteristics of control subjects and MAP abusers. 
Variable    Controls   Abusers   p Values 
Sex, M/F    157/42   149/40   0.989* 
Age, mean ± SD, y  37.2 ± 10.5 (19-73) 36.9 ± 11.9 (18-69) 0.813** 
Prognosis of Psychosis 
Transient type      94 
  Prolonged type      65 
Spontaneous Relapse 
  Positive      62 
  Negative      111 
Poly-substance Abuse 
  No       55 
  Yes       116 
*The comparison between 2 groups was performed using the x2 test. 
**The comparison between 2 groups was performed using the t test.  
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Table 2. Genotype and allele frequencies of the GSTP1 exon 5 gene polymorphism in controls and MAP abusers 
 
Ile105Val (A>G) n Genotype     p  Allele    p 
rs947894   AA  AG  GG    A  G 
 
Control  199 167 (83.9 %) 32 (16.1 %) 0 (0 %)    366 (92.0 %) 32 (8.0 %)  
  
Abuser  189 144 (76.2 %) 41 (21.7 %) 4 (2.1 %) 0.029*  329 (87.0 %) 49 (13.0 %)     0.026* 
 
Prognosis of Psychosis (n=159)      0.013*            0.014* 
Transient 94 71 (75.5 %) 21 (22.3 %) 2 (2.1 %) 0.045*  163 (86.7 %) 25 (13.3 %)     0.052  
Prolonged 65 48 (73.8 %) 15 (23.1 %) 2 (3.1 %) 0.028*  111 (85.4 %) 19 (14.6 %)     0.039* 
 
Spontaneous Relapse 
Positive 62 50 (80.6 %)     11 (17.7 %)        1 (1.6 %)      0.255          111 (89.5 %)     13 (10.5 %)     0.463 
Negative 111 81 (73.0 %)     27 (24.3 %)        3 (2.7 %)      0.009**        189 (85.1 %)     33 (14.9 %)     0.009**          
 
Poly-substance Abuse 
No  55 44 (80.0 %) 9 (16.4 %) 2 (3.6 %) 0.065  97 (88.2 %) 13 (11.8 %)    0.254 
Yes  116 87 (75.0 %) 28 (24.1 %) 1 (0.9 %) 0.052  202 (87.1 %) 30 (12.9 %)    0.053     
 
*P<0.05, **P<0.01 as compared to control (Fisher’s exact test) 
